Mara Goldstein
Stock Analyst at Mizuho
(2.68)
# 1,978
Out of 4,944 analysts
77
Total ratings
43.1%
Success rate
5.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Outperform | $32 → $30 | $6.49 | +362.25% | 3 | May 19, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $30 → $10 | $2.45 | +308.16% | 5 | May 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $9 → $8 | $8.02 | -0.25% | 7 | Apr 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $10.06 | +317.50% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $7.72 | +547.67% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $13.45 | +234.57% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $85.85 | -10.31% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $1.63 | +330.77% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $1.13 | +607.96% | 5 | Nov 20, 2023 | |
| LPTX Leap Therapeutics | Maintains: Buy | $20 → $12 | $0.34 | +3,439.82% | 5 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $90 | $25.72 | +249.92% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $5.00 | -30.00% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $2.29 | +15,620.52% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $3.22 | +521.12% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $82.71 | +57.18% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $1.78 | +12.68% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $1.84 | +552.17% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $0.08 | +11,408.95% | 3 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $36.88 | -45.77% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $6.00 | +700.00% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $24.99 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $5.75 | +143.48% | 1 | Oct 12, 2017 |
Kura Oncology
May 19, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $6.49
Upside: +362.25%
Iovance Biotherapeutics
May 12, 2025
Maintains: Outperform
Price Target: $30 → $10
Current: $2.45
Upside: +308.16%
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $8.02
Upside: -0.25%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $10.06
Upside: +317.50%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $7.72
Upside: +547.67%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $13.45
Upside: +234.57%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $85.85
Upside: -10.31%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $1.63
Upside: +330.77%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $1.13
Upside: +607.96%
Leap Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $20 → $12
Current: $0.34
Upside: +3,439.82%
Aug 7, 2023
Reiterates: Neutral
Price Target: $90
Current: $25.72
Upside: +249.92%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $5.00
Upside: -30.00%
Apr 24, 2023
Reiterates: Buy
Price Target: $360
Current: $2.29
Upside: +15,620.52%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $3.22
Upside: +521.12%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $82.71
Upside: +57.18%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $1.78
Upside: +12.68%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $1.84
Upside: +552.17%
Nov 9, 2022
Upgrades: Buy
Price Target: $9
Current: $0.08
Upside: +11,408.95%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $36.88
Upside: -45.77%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $6.00
Upside: +700.00%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $24.99
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $5.75
Upside: +143.48%